17,261 trials
Non-alcoholic Fatty Liver Disease (NAFLD · Hypertriglyceridemia
Primary: Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Placebo) — 0.98; 1.04 ratio of % liver fat — p=0.407
HIV-1 Infection · Tuberculosis
Primary: Percent of Participants With DMPA Concentrations Below 0.1 ng/mL at Week 12 — 11.9 percentage of participants
Obesity
Primary: Number of Episodes of Diarrhea (Part A and Part B) — 1.67; 1.25; 0.38; 1.88 Number of stools — p=0.202
Diabetic Macular Edema
Primary: Mean Change in Visual Acuity Letter Score — 2.7; 3.0 Letter Score
Metastatic Prostate Cancer
Primary: To Evaluate Peripheral PA2024-specific T Cell Proliferation Response to Sipuleucel-T Over Time Via a T Cell Stimulation Index (SI). — 2.48; 1.48; 8.76; 5.08 10^3…
Congestion, Nasal
Primary: Change From Baseline in Mean Total Score of the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) for Each Domain (Sleep, Sleep Time, Symptoms on…
Myelodysplastic Syndromes
Primary: Response to Treatment - Hematologic Improvement or Complete Response — 21 Participants
Alzheimer's Disease
Primary: Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24 — -6.3; 33.6; -77.4; -327.7 Nanograms per Liter…
Prostate Cancer
Primary: Percentage of Patients With Undetectable PSA (Prostate-Specific Antigen) at 1 Year — 54.54 percentage of participants
Pulmonary Arterial Hypertension
Primary: Difference in Ambulatory 6 Minute Walk Distance (6MWD) Pulmonary Artery (PA) Pressures (Systolic, Diastolic, Mean) Between the Post-intervention (iNO+) and…
Alcohol Use Disorder
Primary: Percentage of Subjects With no Heavy Drinking Days (PSNHDD) — 17.3; 24.1 percentage of subjects with NHDD
Acute Liver Failure · Acute Liver Injury
Primary: Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability — 0; 0…
Leukemia, Myeloid
Primary: Number of Participants Who Achieved a Morphologic Complete Response Within the First Four Cycles of Lenalidomide Treatment According to the Modified International…
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging…
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28 C-Reactive Protein (DAS28 (CRP)) at Week 12 — -1.26; -0.78; -2.46; -1.36 units on a scale — p=0.978